Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

被引：3

作者：

Iskierka-Jazdzewska, Elzbieta ^{[1
]}

Kim, Won Seog ^{[2
]}

Cho, Seok-Goo ^{[3
]}

Kim, Tae Min ^{[4
]}

Jarque, Isidro ^{[5
]}

Robak, Tadeusz ^{[6
]}

Poon, Michelle ^{[7
]}

Prince, H. Miles ^{[8
,9
]}

Yong, Sung ^{[10
]}

Lim, Francesca ^{[11
]}

Carpio, Cecilia ^{[12
]}

Tan, Tran-Der ^{[13
]}

Ayyappan, Sabarish ^{[14
]}

Gutierrez, Antonio ^{[15
]}

Zhang, Huilai ^{[16
]}

Cao, Junning ^{[17
,18
]}

Zhang, Mingzhi ^{[19
,20
]}

Tessoulin, Benoit ^{[21
,22
]}

Li, Jingjin ^{[23
]}

Ivanescu, Cristina ^{[24
]}

机构：

[1] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland

[2] Samsung Med Ctr, Ctr Hematol Malignancy, Seoul, South Korea

[3] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[5] Hosp Univ La Fe, Valencia, Spain

[6] Med Univ Lodz, Lodz, Poland

[7] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore

[8] Epworth Healthcare, Melbourne, Vic, Australia

[9] Univ Melbourne, Melbourne, Vic, Australia

[10] Dong A Univ Hosp, Busan, South Korea

[11] Singapore Gen Hosp, Singapore, Singapore

[12] Vall DHebron Hosp, Barcelona, Spain

[13] Koo Fdn Sun Yat Sen Canc Ctr, Taipei, Taiwan

[14] Univ Iowa Hosp & Clin, Iowa City, IA USA

[15] Hosp Univ Son Espases, IdISBa Palma, Palma de Mallorca, Spain

[16] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China

[17] Fudan Univ, Dept Lymphoma, Shanghai Canc Ctr, Shanghai, Peoples R China

[18] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[19] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[20] Lymphoma Diag & Treatment Ctr Henan Prov, Zhengzhou, Peoples R China

[21] Nantes Univ, Sch Med, Nantes, France

[22] Univ Hosp Nantes, Nantes, France

[23] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[24] IQVIA, Amsterdam, Netherlands

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180743

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[1] Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Ayyappan, Sabarish
Kim, Won Seog
Kim, Tae Min
Walewski, Jan
Cho, Seok-Goo
Jarque, Isidro
Iskierka-Jazdzewska, Elzbieta
Poon, Michelle
Oh, Sung Yong
Lim, Francesca Lorraine Wei Inng
Carpio, Cecilia
Tan, Tran-Der
Gutierrez, Antonio
Zhang, Huilai
Cao, Junning
Zhang, Mingzhi
Tessoulin, Benoit
Li, Jingjin
Ufkin, Melanie
Shariff, Saleem
Chi, Lei
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Prince, H. Miles
BLOOD, 2023, 142
[2] Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Kim, Won Seog
Kim, Tae Min
Cho, Seok-Goo
Jarque, Isidro
Iskierka-Jazdzewska, Elzbieta
Poon, Li Mei
Prince, H. Miles
Zhang, Huilai
Cao, Junning
Zhang, Mingzhi
Tessoulin, Benoit
Oh, Sung Yong
Lim, Francesca
Carpio, Cecilia
Tan, Tran-Der
Ayyappan, Sabarish
Gutierrez, Antonio
Cai, Jingxian
Ufkin, Melanie
Sharif, Saleem
Brouwer-Visse, Jurriaan
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Walewski, Jan
NATURE CANCER, 2025, 6 (03) : 528 - 539
[3] Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog
Kim, Tae Min
Cho, Seok-Goo
Jarque, Isidro
Iskierka-Jazdzewska, Elzbieta
Poon, Michelle Limei
Prince, H. Miles
Oh, Sung Yong
Lim, Francesca
Carpio, Cecilia
Tran-Der Tan
Ayyappan, Sabarish
Gutierrez, Antonio
Li, Jingjin
Ufkin, Melanie
Zhu, Min
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth R.
Walewski, Jan
BLOOD, 2022, 140 : 1070 - 1071
[4] Health-related quality of life (HRQoL), functioning, and symptoms with odronextamab monotherapy in patients (pts) with relapsed or refractory follicular lymphoma (R/R FL) by POD24 status in the ELM-2 study.
Villasboas, Jose Caetano
Mayer, Laura Magnano
Tessoulin, Benoit
Cho, Seok-Goo
Taszner, Michal
Novelli, Silvana
Luminari, Stefano
Merli, Michele
Ubieto, Ana Jimenez
Poon, Michelle
Tucker, David
Walewski, Jan Andrzej
Ivanescu, Cristina
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth R.
Harnett, James
Kamat, Siddhesh
Kim, Tae Min
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Spira, Alexander
Zhou, Xiaolei
Chen, Lei
Gnanasakthy, Ari
Wang, Luqiang
Ungar, David
Curiel, Rafael
Liao, Laura
Radford, John
Kahl, Brad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : 158 - 168
[6] Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies
Zhu, Min
Conrado, Daniela
Srinivasan, Kamal
Brouwer-Visser, Jurriaan
Yan, Hong
Mohamed, Hesham
Chaudhry, Aafia
Ambati, Srikanth
Harnisch, Lutz
Davis, John D.
BLOOD, 2023, 142
[7] Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma
Spira, Alexander I.
Chen, Lei
Zhou, Xiaolei
Gnanasakthy, Ari
Wang, Luqiang
Ungar, David
Curiel, Rafael
Radford, John A.
Kahl, Brad S.
BLOOD, 2020, 136
[8] Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
Shah, Jatin
Shacham, Sharon
Kauffman, Michael
Daniele, Patrick
Tomaras, Dimitrios
Tremblay, Gabriel
Casasnovas, Rene-Olivier
Maerevoet, Marie
Zijlstra, Josee
Follows, George
Vermaat, Joost S. P.
Kalakonda, Nagesh
Goy, Andre Henri
Choquet, Sylvain
Van den Neste, Eric
Hill, Brian T.
Thieblemont, Catherine
Cavallo, Federica
de la Cruz, Fatima
Kuruvilla, John
Hamad, Nada
Bouabdallah, Reda
Jager, Ulrich
Caimi, Paolo
Gurion, Ronit
Warzocha, Krzysztof
Bakhshi, Sameer
Sancho, Juan Manuel
Schuster, Michael
Egyed, Miklos
Offner, Fritz
Vasilakopoulos, Theodoros P.
Samal, Priyanka
Nagy, Agnes
Ku, Matthew
Canales Albendea, Miguel Angel
FUTURE ONCOLOGY, 2021, 17 (11) : 1295 - 1310
[9] Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
Chong, Geoffrey
Taszner, Michal
Novelli, Silvana
Cho, Seok-Goo
Villasboas, Jose C.
Ubieto, Ana Jimenez
Tessoulin, Benoit
Poon, Michelle
Tucker, David
Walewski, Jan
Song, Yuqin
Bachy, Emmanuel
Guidez, Stephanie
Alonso, Aranzazu
Jagadeesh, Deepa
Luminari, Stefano
Mayer, Laura Magnano
Iskierka-Jazdzewska, Elzbieta
Tani, Monica
Cai, Jingxian
Uppala, Amulya
Shariff, Saleem
Brouwer-Visser, Jurriaan
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Kim, Tae Min
CANCER RESEARCH, 2024, 84 (07)
[10] Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)
Phillips, Tycel
Lugtenburg, Pieternella
Kalsekar, Anupama
Mutebi, Alex
Wang, Anthony
Blaedel, Julie
Kosa, Katherine
Martin, Susan
Sacchi, Mariana
Thieblemont, Catherine
BLOOD, 2022, 140 : 8022 - 8023

← 1 2 3 4 5 →